Biogen is realigning resources for its Alzheimer's Disease Franchise with significant activities surrounding its Alzheimer's drug
Leqembi. The company's Q2 earnings and sales beat estimates due to increasing traction from Leqembi and other new products. Multiple efforts are in progress to expand Biogen's rare disease pipeline, including its recent acquisition of
HI-Bio. Biogen's revenue did experience a slump due to Aduhelm costs and weaker sales of multiple sclerosis therapies. However, overall profit was better than expected, largely due to successful cost-cutting measures. Regulatory receptions of Alzheimer's drugs have been mixed; while Biogen’s
Qalsody received EU approval, its Alzheimer's drug faced rejection in Europe. Biogen completed the acquisition of
Human Immunology Biosciences to broaden its Immunology Portfolio. A major setback came when the development of an experimental ALS drug was discontinued. However, new promising data from an
Investigational Antisense Oligonucleotide indicates potential new treatments for early Alzheimer's disease. Despite perceived weak fundamentals and a class-action lawsuit, some experts maintain the view that Biogen offers value for long term investment.
Biogen BIIB News Analytics from Tue, 26 Sep 2023 07:00:00 GMT to Sun, 01 Sep 2024 03:58:00 GMT -
Rating 3
- Innovation 5
- Information 8
- Rumor 2
